AnGes, Inc. has entered a collaboration agreement with Brickell Biotech, Inc., a clinical-stage pharmaceutical company, under which Brickell has the right to develop AnGes’ investigational adjuvanted plasmid DNA vaccine intended to prevent SARS-CoV-2 (COVID-19) in the U.S., South America and certain emerging markets. AnGes is currently conducting Phase 1/2 clinical studies in Japan, with data expected through 1Q21. The results from these studies will guide AnGes’ and Brickell’s global developmen...